JATT Acquisition registered with the SEC to offer 12 million units at $10 each to raise capital for the acquisition of a life sciences business.
Each unit consists of one Class A ordinary share and one-half of one redeemable warrant, with whole warrants exercisable for a share at $11.50.
Raymond James is sole book-running manager for the offering. The underwriters have a 45-day option to purchase up to an additional 1.8 million units to cover any over-allotments.
JATT’s focus on the life sciences sector will emphasize companies utilizing the application of machine learning techniques and structure-based drug design to improve the therapeutic development process.
Dr. Someit Sidhu is CEO and director of the new SPAC. He is also the co-founder and CEO of Akaza Bioscience and the CEO of Izana Bioscience, as well as the co-founder of Pathios Therapeutics.
The SPAC intends to apply for a listing on the NYSE under JATT.U. Read more.
